1/16
08:10 am
krys
Krystal Biotech: Beyond VYJUVEK Commercialization [Seeking Alpha]
Low
Report
Krystal Biotech: Beyond VYJUVEK Commercialization [Seeking Alpha]
1/12
03:58 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.
1/11
01:16 pm
krys
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/11
01:00 pm
krys
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/10
07:02 pm
krys
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing [Yahoo! Finance]
Medium
Report
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing [Yahoo! Finance]
1/10
07:02 pm
krys
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update [Yahoo! Finance]
Medium
Report
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update [Yahoo! Finance]
1/10
02:18 am
krys
Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run [Yahoo! Finance]
Medium
Report
Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run [Yahoo! Finance]
1/9
02:47 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at TD Cowen from $202.00 to $306.00. They now have a "buy" rating on the stock.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at TD Cowen from $202.00 to $306.00. They now have a "buy" rating on the stock.
1/9
09:02 am
krys
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/9
07:18 am
krys
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/9
06:10 am
krys
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/8
10:16 pm
krys
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path [Yahoo! Finance]
Medium
Report
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path [Yahoo! Finance]
1/8
04:56 pm
krys
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis [Yahoo! Finance]
Medium
Report
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis [Yahoo! Finance]
1/8
04:01 pm
krys
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
Medium
Report
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
1/7
04:05 pm
krys
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Low
Report
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
1/6
08:02 am
krys
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
Low
Report
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
1/5
08:00 am
krys
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
12/10
04:46 am
krys
Understanding the Genetics of ARCI: Rare but Highly Impactful Skin Disorders [Yahoo! Finance]
Low
Report
Understanding the Genetics of ARCI: Rare but Highly Impactful Skin Disorders [Yahoo! Finance]
12/9
04:25 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:10 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
08:28 am
krys
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Low
Report
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
11/26
08:00 am
krys
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
Low
Report
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
11/19
01:42 pm
krys
Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT [Yahoo! Finance]
Low
Report
Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT [Yahoo! Finance]
11/16
09:01 am
krys
Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth [Seeking Alpha]
Low
Report
Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth [Seeking Alpha]
11/14
01:15 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.